TP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited.

ABSTRACT:

Introduction

TP53 is the most commonly mutated gene in human cancers and was the first tumor suppressor gene to be discovered in the history of medical science. Mutations in the TP53 gene occur at various genetic locations and exhibit significant heterogeneity among patients. Mutations occurring primarily within the DNA-binding domain of TP53 result in the loss of the p53 protein's DNA-binding capability. However, a complex phenotypic landscape often combines gain-of-function, dominant negative, or altered specificity features. This complexity poses a significant challenge in developing an effective treatment strategy, which eradicates TP53-mutated cancer clones. This review summarizes the current understanding of TP53 mutations in AML and their i

SUBMITTER: Shin DY 

PROVIDER: S-EPMC10571655 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature